TVARDI THERAPEUTICS, INC.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $21.0M | $41.9M | $23.0M | $135.1M | $19.9M | $13.5M | $911.0K |
| Cost of Revenue | — | — | — | $0 | — | — | — | — |
| Gross Profit | — | — | — | $23.0M | — | — | — | — |
| Gross Margin | — | — | — | 100.0% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $23.7M | $108.5M | $91.9M | $82.7M | $107.9M | $113.8M | $75.5M | $48.5M |
| SG&A Expense | $4.5M | $27.8M | $30.3M | $29.4M | $21.8M | $17.7M | $15.3M | $11.9M |
| Operating Income | $-28.1M | $-121.5M | $-87.5M | $-89.1M | $5.4M | $-111.7M | $-77.4M | $-59.5M |
| Operating Margin | -393.8% | -579.4% | -209.1% | -386.8% | 4.0% | -561.6% | -574.5% | -6,529.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-71.3M | $-118.5M | $-85.5M | $-88.4M | $7.7M | $-107.2M | $-74.4M | $-58.3M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $-691.0K | $-816.0K | $-389.0K | $-204.0K |
| Net Income | $-29.4M | $-118.5M | $-85.5M | $-88.4M | $8.4M | $-106.4M | $-74.0M | $-58.1M |
| Net Margin | -411.9% | -565.2% | -204.2% | -384.1% | 6.2% | -534.9% | -549.5% | -6,380.4% |
| EPS (Basic) | $-3.81 | $-8.75 | $-6.37 | $-0.58 | $0.06 | $-0.83 | $-0.69 | $-0.62 |
| EPS (Diluted) | $-3.81 | $-8.75 | $-6.37 | $-0.58 | $0.06 | $-0.83 | $-0.69 | $-0.62 |
| Shares Outstanding (Basic) | 7.7M | 13.5M | 13.4M | 152.2M | 142.2M | 128.0M | 107.7M | 93.6M |
| Shares Outstanding (Diluted) | 7.7M | 13.5M | 13.4M | 152.2M | 143.7M | 128.0M | 107.7M | 93.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |